Blood markers that predict islet autoimmunity and type 1 diabetes
Official title: Systematic validation of biomarkers predictive of IA and T1D and their relationship with disease development
Funded at Battelle Pacific Northwest Laboratories · NIH-11261101 · Data updated 2026-11-12
This project looks at specific blood proteins to see which children at increased risk will develop islet autoimmunity or type 1 diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Battelle Pacific Northwest Laboratories NIH-funded |
| Lab location | 1 site (Richland, United States) |
| Project start | January 17, 2024 |
| Project end | December 31, 2026 |
| Funding year | 2026 |
| Award (this year) | $482,550 |
| NIH project number | 5R01DK138335-03 |
| Project ID | NIH-11261101 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are children and adolescents with increased genetic or family risk for type 1 diabetes or those already enrolled in longitudinal monitoring programs for islet autoimmunity.
✕Less likely to help
People without increased genetic or familial risk for type 1 diabetes or those not participating in a research cohort are unlikely to receive direct benefit from this study.
What this research studies
Researchers will measure hundreds of proteins in blood samples from children and young people drawn from previous studies (including TEDDY) and additional cohorts. They will use advanced proteomics and machine-learning models to identify panels of proteins that appear before autoantibodies or clinical diabetes. The team plans to validate previously identified candidate proteins across a wider age range and with longer follow-up to see which markers reliably track disease stages. This work is aimed at finding blood signals that could flag who needs closer monitoring or who might be eligible for early prevention efforts.
Why it matters
Potential benefit: If successful, validated blood markers could enable earlier identification of children likely to develop islet autoimmunity or type 1 diabetes, allowing closer monitoring or earlier entry into prevention trials.
How similar studies have gone: Earlier TEDDY proteomics work found promising protein panels that predicted islet autoimmunity and progression (AUCs ≈0.92 and 0.87), but broader validation across ages and longer follow-up is still needed.
Where this research is happening
-
Battelle Pacific Northwest Laboratories
Richland, United States Active
Researchers
- Principal investigator: Nakayasu, Ernesto Satoshi — Battelle Pacific Northwest Laboratories
- Study coordinator: Nakayasu, Ernesto Satoshi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.